Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement

Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement. A Randomized Clinical Trial

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06585852

Enrollment

Registered

2024-09-19

Start date

2023-08-01

Completion date

2024-10-15

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implant Dentistry

Brief summary

The aim of the present study is to evaluate the efficacy of xenograft alone or xenograft mixed with Arginylglycylaspartic acid (RGD) , in horizontal ridge augmentation with split-crest technique, for implant placement.

Detailed description

A comparative study for ridge augmentation procedure, With two groups. First group underwent a surgical ridge splitting procedure with ultrasonic bone surgery and grafting with Xenograft alone and implant placement. Second group underwent a surgical ridge splitting procedure with ultrasonic bone surgery Xenograft mix ed with Arginylglycylaspartic acid (RGD) and implant placement. Both groups were followed up for 1 and 3 months after loading.

Interventions

DRUGRGD

Study group main material

DRUGXenograft

Scaffold material of choice

PROCEDURESplit crest technique

Piezoelectric surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 30 Years

Healthy volunteers

Yes

Inclusion criteria

1. Adults (age 18-30) exhibiting initial insufficiently bone width. 2. Patients with good oral hygiene. 3. Patients must be free from systemic diseases that may influence the outcome of the therapy. 4. Patients with bony horizontal defects alone, Class III & IV.

Exclusion criteria

1. Heavy smokers. 2. Patient treated by immunosuppressive chemotherapy or radio therapy, 3. Allergy to any material or medication used in the study. 4. Pregnant females.

Design outcomes

Primary

Measure	Time frame	Description
ISQ measurement for implant stability	At time of surgery, at loading and 3 months after loading.	Evaluate implant stability by osstell device

Secondary

Measure	Time frame	Description
Bone density around dental implants.	At time of loading and 3 months after loading	Evaluation of bone density after ridge splitting and implant placement

Countries

Egypt

Contacts

Primary ContactMahmoud Taha, PHD

info@azhar.edu.eg01225864104

Backup ContactIbrahim Sabri

info@azhar.edu.eg01007809113

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026